Footnotes

• Correction notice This article has been corrected since it first published. The provenance and peer review statement has been included.

• Contributors Both authors contributed equally to the writing of this article.

• Funding ARL is supported by the Fondation Leducq Network of Excellence in Cardio-Oncology.

• Competing interests ARL has received speaker, advisory board or consultancy fees and/or research grants from Pfizer, Novartis, Servier, Amgen, Takeda, Roche, Janssens-Cilag Ltd, Clinigen, Eli Lily, Eisai, Bristol Myers Squibb, Ferring Pharmaceuticals, Boehringer Ingelheim, Myocardial Solutions, iOWNA and Heartfelt Technologies Ltd.

• Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

• Provenance and peer review Commissioned; externally peer reviewed.

• Author note References which include a * are considered to be key references.